Nuvation Bio Inc. Debt Related Commitment Fees and Debt Issuance Costs
Nuvation Bio Inc. (NUVB) reported Debt Related Commitment Fees and Debt Issuance Costs of $4.66 million for the 6-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2026-03-02
- Nuvation Bio Inc. debt related commitment fees and debt issuance costs for the quarter ending 2025-09-30 was $4.66M.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs | Debt Related Commitment Fees and Debt Issuance Costs 3 month | Debt Related Commitment Fees and Debt Issuance Costs 6 month |
|---|---|---|---|
| 2025-12-31 | $4.66M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $4.66M 10-Q · filed 2025-11-03 | ||
| 2025-06-25 | $4.67M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |